MBRX (STOCKS)
Moleculin Biotech, Inc.
$4.110000
-0.070000 (-1.67%)
Prev close: $4.180000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Walter V. Klemp
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $12.98M
- Employees
- 17
- P/E (TTM)
- -0.07
- P/B (TTM)
- -0.31
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
6
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-17.00 | $-4.97 | -12.0275 | -241.88% |
|
Jun 2025 (Q2)
|
$-12.25 | $-9.26 | -2.9851 | -32.22% |
|
Mar 2025 (Q1)
|
$-17.25 | $-14.15 | -3.0975 | -21.89% |
|
Dec 2024 (Q4)
|
$-9.33 | $-32.72 | +23.3999 | +71.50% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $24.21M |
| Research and Development | $15.23M |
| Other Operating Expenses | $8.98M |
| Operating Income/Loss | -$24.21M |
| Income/Loss From Continuing Operations After Tax | -$51.41M |
| Income/Loss From Continuing Operations Before Tax | -$51.41M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$51.41M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$51.41M |
| Net Income/Loss Available To Common Stockholders, Basic | -$51.41M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.99 |
| Basic Average Shares | 21,359,451 |
| Assets | $20.35M |
| Current Assets | $7.89M |
| Noncurrent Assets | $12.47M |
| Fixed Assets | $77.00K |
| Other Non-current Assets | $12.39M |
| Liabilities | $47.27M |
| Current Liabilities | $5.68M |
| Accounts Payable | $2.12M |
| Wages | $1.35M |
| Other Current Liabilities | $2.21M |
| Noncurrent Liabilities | $41.59M |
| Equity | -$26.92M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$26.92M |
| Liabilities And Equity | $20.35M |
| Net Cash Flow From Operating Activities | -$22.45M |
| Net Cash Flow From Operating Activities, Continuing | -$22.45M |
| Net Cash Flow From Investing Activities | -$2.43M |
| Net Cash Flow From Investing Activities, Continuing | -$2.43M |
| Net Cash Flow From Financing Activities | $19.80M |
| Net Cash Flow From Financing Activities, Continuing | $19.80M |
| Exchange Gains/Losses | -$48.00K |
| Net Cash Flow | -$5.12M |
| Net Cash Flow, Continuing | -$5.08M |
| Comprehensive Income/Loss | -$51.46M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$51.46M |
| Other Comprehensive Income/Loss | -$51.46M |